B+
Bull case
20%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
VVOS
Vivos TherapeuticsCNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$0.30
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.10
Analysis reference price unavailable
Analysis 2026-08-18 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-18
Recent news sentiment (30D)
+28.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
+28.0
Positive
Sentiment proxy
+53.0
Score
AI commentary
Headline flow is sparse and social coverage is absent. The post-print price reaction, consensus surprise, analyst revisions, and target changes are unavailable. Q2 operating results were constructive, but the going-concern warning and equity-financing dependence keep sentiment fragile and support a monitoring stance.
RankAlpha Sentiment Codex - 2026-08-18
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-18eventQ2 revenue growth and margin improvement confirmedHigh impact
The June-quarter 10-Q reported $5.153 million of revenue versus $3.820 million year over year, gross profit of approximately $3.0 million, gross margin of 57% versus 55%, and a slightly improved operating loss. The earnings transcript confirms management reviewed Q2 results and 2026 plans, but consensus surprise and guidance revisions are unavailable [#SEC-10Q-2026-08-14] [#EARNINGS-TRANSCRIPT-2026Q2].
2026-09-30catalystLiquidity and dilution remain the immediate stock variableHigh impact
The 10-Q reported approximately $1.8 million of cash at June 30, 2026, stated that this would not fund operations and strategic objectives for the next twelve months, and disclosed substantial going-concern doubt without additional financing. Management expects financing to rely primarily on equity issuance, creating dilution and Nasdaq-compliance risk [#SEC-10Q-2026-08-14].
2026-12-31catalystSCN model must convert patient volume into cash-flow-positive scaleHigh impact
The filing says the SCN acquisition increased patient volume, top-line revenue, and lowered customer-acquisition costs, but revenues remain insufficient to cover expenses. The medical-provider model is new and unproven, while Rebis Health delays have reduced revenue expectations; durable upside requires sustained service growth, margin improvement, and financing without another capital reset [#SEC-10Q-2026-08-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-18 • Updated nightlySource: Internal modelMethodology